Effects on Experimental Dyspnea of High Flow Nasal Cannula

NCT ID: NCT03469037

Last Updated: 2019-02-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-22

Study Completion Date

2018-11-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To develop an experimental model of dyspnea by external thoraco-abdominal elastic strapping at rest in order to study the mechanisms involved in the relief of dyspnea by the administration of high flow by nasal cannula (HFNC).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will measure the effect of HFNC on an experimental model of dyspnea induced by thoraco-abdominal elastic strapping on healthy subjects at rest.

The study will also compare the effects on dyspnea of the administration of high flow nasal cannula with and without oxygen added.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyspnea Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oxygen first

Optiflow with an inspired fraction of oxygen of 100% in the first seance Optiflow with an inspired fraction of oxygen of 21 % in the second seance

Group Type EXPERIMENTAL

Optiflow with an inspired fraction of oxygen of 100%

Intervention Type DEVICE

Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 100%

Optiflow with an inspired fraction of oxygen of 21%

Intervention Type DEVICE

Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 21%

Air first

Optiflow with an inspired fraction of oxygen of 21 % in the first seance Optiflow with an inspired fraction of oxygen of 100 % in the second seance

Group Type EXPERIMENTAL

Optiflow with an inspired fraction of oxygen of 100%

Intervention Type DEVICE

Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 100%

Optiflow with an inspired fraction of oxygen of 21%

Intervention Type DEVICE

Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 21%

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Optiflow with an inspired fraction of oxygen of 100%

Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 100%

Intervention Type DEVICE

Optiflow with an inspired fraction of oxygen of 21%

Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 21%

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

High flow nasal cannula with oxygen added High flow nasal cannula without oxygen added

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy volunteers

Exclusion Criteria

* chronic pathology
* active smokers
* anxiety disorder
* allergy to latex
* protected adult
* woman declared herself pregnant
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Capucine Morelot-Panzini, Doctor

Role: PRINCIPAL_INVESTIGATOR

Service de Pneumologie de la Pitié-Salpétrière

Thomas Similowski, PHD

Role: STUDY_DIRECTOR

Service de Pneumologie de la Pitié-Salpétrière

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Laboratoire de Physiopathologie Respiratoire du Service de Pneumologie et de Réanimation

Paris, , France

Site Status

Service de Pneumologie et Réanimation Médicale

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-A00178- 47

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.